CONy Multiple Sclerosis Debates

Print

Friday March 23, 2018

MS is primarily an inflammatory disease with secondary neurodegeneration.
Host: Joab Chapman, Israel
Pro: Heinz Wiendl, Germany
Con: Alicja Kalinowska, Poland
Discussions and Rebuttals

In patients with clinical evidence of MS-like disease and a confirmatory MRI,
CSF examination can be avoided in most cases.
Host: Ralf Linker, Germany
Pro: Jacek Losy, Poland
Con: Uros Rot, Slovenia
Discussions and Rebuttals

Cognitive dysfunction in MS is improved by disease modifying drugs (DMD)
This webcast is supported by Novartis
Host: Friedemann Paul,
Germany
Pro: Alicja Kalinowska,
Poland
Con: Joao Jose Araujo
Cerqueira, Portugal
Discussions and Rebuttals

Progressive forms of MS respond to agents used for relapsing forms of the disease.
Host: David Leppert,
Switzerland
Pro: Ron Milo,
Israel
Con: Robert Zivadinov,
USA
Discussions and Rebuttals

Second line therapies should be first line in patients with aggressive MS.
Host: Ralf Linker, Germany
Pro: Jacek Losy, Poland
Con: Thomas Müller, Germany
Discussions and Rebuttals

Bone marrow transplantation is the ultimate treatment in aggressive disease.
Host: Krzystof Selmaj, Poland
Pro: Mark Freedman, Canada
Con: Brian Weinshenker, USA
Discussions and Rebuttals

Should treatment be stopped in MS patients who had an apparently inactive diseases for 5 years?
This webcast is supported by Merck
Host: David Leppert,
Switzerland
Pro: Adam Czaplinski,
Switzerland
Con: Dimitrios Karussis,
Israel
Discussions and Rebuttals

Is the switch from ethical to generic MS drugs safe and justified?
Host: Dimitrios Karussis, Israel
Pro: Olaf Stuve, USA
Con: Ron Milo, Israel
Discussions and Rebuttals